



FDA's and NCATS' CURE ID app for RWD to inform the design of trials for drug candidates against Valley Fever

Klaus Romero MD MS FCP
Chief Science Officer



- FDA-NIH (NCATS) collaboration
- Web-based tool
- Capture and share real-world experiences treating patients through a simple online case report form
- Smartphone, computer or mobile device

<https://cure.ncats.io/explore>

CONTRIBUTE

Contribute your knowledge and expertise to this global health open-source community

Enter or update a case
Participate as a curator
Get involved in the initiative

EXPLORE

Explore experiences of clinicians globally and stay up to date on the latest ID news

Search by disease
View clinical trials
Look up published cases
Review user-submitted cases

DISCUSS

Discuss and share your most challenging clinical cases and treatment questions

Ask your questions and get replies
View discussion posts and comment
Consult with colleagues

-
- Use this real-world data to generate hypotheses about potentially safe and effective repurposed therapies for Valley fever, which be studied in more formal clinical trials
 - Facilitate labeling that accurately reflects a drug's efficacy in clinical practice, harnessing a combination of traditional trials and real-world evidence
 - Serve as a global one-stop-shop of information and high-quality data, and as a medical education tool for clinicians on challenging and unusual infectious disease cases, like Valley fever

- Mission

- Become the central global source of validated real-world data to advance drug repurposing for diseases with the highest levels of unmet medical need

- Values

- Transparency (open data model, data easily accessible through CURE ID, ensure data privacy)
- Inclusiveness (capture and share data globally)
- Data stewardship (data reviewed and curated to the extent possible for aggregation and analysis)
- Collaboration (PPP initiated to facilitate collaboration, inform clinical trials)
- Common good (share RWD treatment and outcome information broadly, facilitate regulatory engagement, support drug relabeling for new indication)


- Vision

- We will work to ensure that every patient has treatment available for their disease

- Purpose

- We believe that real-world evidence can be used to help guide how existing drugs can be used in new ways to improve clinical outcomes for diseases when approved therapies are unavailable or have been exhausted

Collaboratory Structure





Thank You